828252-28-4

Upstream product

• 828252-27-3 (4-methoxy-3-trifluoromethanesulfonyloxy-phenyl)-acetic acid methyl ester 
• 557-21-1 dicyanozinc 
• 19626-36-9 methyl 2-(3-bromo-4-methoxyphenyl)acetate 
• 774-81-2 (3-bromo-4-methoxy-phenyl)-acetic acid 
• 15964-81-5 methyl 3-hydroxy-4-methoxyphenylacetate 
• 1131-94-8 homoisovanillic acid 

Downstream Products

• 828252-29-5 (3-cyano-4-methoxy-phenyl)-acetic acid hydrazide 
• 927187-51-7 (3-{4-[2-(2,4-dichloro-phenoxy)-ethylcarbamoyl]-5-phenyl-isoxazol-3-yl}-4-methoxy-phenyl)-acetic acid methyl ester 
• 562840-55-5 3-formyl-4-methoxyphenylacetic acid methyl ester 

Relevant academic research and scientific papers

ALDOSTERONE SYNTHASE INHIBITORS

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein X, R1, R2 and R3 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

3,4,5-Trisubstituted isoxazoles as novel PPARδ agonists. Part 2

A series of PPARδ-selective agonists was investigated and optimized for a favorable in vivo pharmacokinetic profile. Isoxazole LCI765 (17d) was found to be a potent and selective PPARδ agonist with good in vivo PK properties in mouse (Cmax = 5.1 μM, t1/2 = 3.1 h). LCI765 regulated expression of genes involved in energy homeostasis in relevant tissues when dosed orally in C57BL6 mice. A co-crystal structure of compound LCI765 and the LBD of PPARδ is discussed.